GT-EPIC™ Platform Based Personalized Cancer Vaccines to Treat Patients with Advanced Hepatocellular Carcinoma in Combination with PD1 Checkpoint Immunotherapy

Time: 3:00 pm
day: Day One


  • Sharing clinical data highlighting objective responses evaluated via RECIST 1.1
  • Understanding what can biomarkers inform us for predicting cancer vaccine driven clinical and immunological responses in checkpoint combinations